Archives
-
v-Agatoxin-IVA and Low-Affinity N-Type Ca Blockade
2026-09-13
Sidach and Mintz showed that v-Agatoxin-IVA remains a high-affinity P-type calcium channel blocker but can also inhibit N-type and other high-threshold currents at micromolar exposure. The study demonstrates why toxin selectivity must be interpreted alongside concentration, voltage dependence, gating kinetics, and neuronal preparation.
-
Docetaxel (A4394): Reliable Assay Design
2026-09-12
This scenario-driven guide explains how Docetaxel (SKU A4394) can support better-controlled viability, proliferation, and cytotoxicity assays. It covers mechanism, solvent compatibility, concentration planning, multidrug-resistance interpretation, and practical product selection.
-
Dissecting Cancer Drug Responses In Vitro
2026-09-12
Hannah Schwartz’s dissertation proposes a clearer way to interpret anticancer drug responses by separating proliferative arrest from actual cell killing. Its distinction between relative viability and fractional viability provides a practical framework for improving assay design, timing, and translational interpretation in cancer biology.
-
Naftifine HCl in Cell Viability Assays
2026-09-11
This evidence-based guide explains how Naftifine HCl, SKU B1984, can be incorporated into cell viability, proliferation, and cytotoxicity workflows without confusing antifungal mechanism with mammalian-cell toxicity. It covers solvent control, assay optimization, interpretation of muscle-cell experiments, and practical supplier qualification.
-
U 46619 for Platelet and Vascular Assays
2026-09-11
U 46619 is a concentration-tunable TP-receptor agonist for separating early platelet signaling from later secretion, aggregation, and fibrinogen-receptor responses. This workflow-focused guide explains assay setup, vascular applications, troubleshooting, and practical interpretation of concentration-dependent phenotypes.
-
Iguratimod Prodrug Rewires RA Synovial Crosstalk
2026-09-10
A 2026 Journal of Orthopaedic Translation study identifies TYK2 JH2-dependent STAT1 signaling as a mechanistic link between invasive rheumatoid arthritis fibroblast-like synoviocytes and macrophage inflammation. It also presents AD811, an iguratimod prodrug that preserves experimental efficacy while improving pharmacokinetic behavior, offering a useful framework for studying synovial cell-cell signaling and drug design.
-
Estrogen Receptor–Autophagy Axis in Perimenopause
2026-09-10
This reference study integrates NHANES population data, a perimenopausal mouse model, network pharmacology, and inhibitor-based validation to examine how declining estradiol relates to cardiometabolic and renal vulnerability. Its main contribution is functional evidence that receptor-dependent autophagy helps mediate estrogen-associated protection against fibrosis in the heart, aorta, and kidneys.
-
TMRE Mitochondrial Membrane Potential Assay Guide
2026-09-09
Learn how the TMRE mitochondrial membrane potential assay kit converts ΔΨm changes into mechanistic insight rather than treating fluorescence as a simple apoptosis label. This guide connects TMRE measurements with sodium-driven mitochondrial energy failure, assay controls, interpretation, and scalable experimental design.
-
Balsalazide Disodium: Applied Research Workflows
2026-09-09
Balsalazide Disodium Dihydrate combines water-compatible handling with microbiota-dependent activation, making it useful for colon-targeted inflammation research, radiolabeling development, and inflammatory bowel disease models. This guide translates its 5-aminosalicylic acid prodrug biology into practical protocols, controls, and troubleshooting decisions.
-
GSTA1 and α-Amanitin Hepatotoxicity
2026-09-08
The reference study identifies GSTA1 as an unexpected driver of α-amanitin liver injury rather than a purely protective detoxification enzyme. Using mouse toxicology, HUH7-cell experiments, integrated transcriptomics and metabolomics, molecular docking, DARTS, and genetic perturbation, the authors connect NRF2-associated GSTA1 upregulation with glutathione depletion, reactive oxygen species accumulation, and hepatocyte damage.
-
JHU-083 for Glutaminase Pathway Research
2026-09-07
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase pathway interrogation in cerebral CD11b cells. This guide connects experimental cerebral malaria research with practical glutamate, redox, multi-omics, and troubleshooting workflows while clearly separating established evidence from exploratory applications.
-
G007-LK Tankyrase 1/2 Inhibitor Guide
2026-09-07
A scenario-driven guide to using G007-LK tankyrase 1/2 inhibitor in viability, proliferation, and cytotoxicity workflows. It explains how SKU B5830 supports mechanistic Wnt, β-catenin, and Hippo-pathway studies while addressing dosing, formulation, interpretation, and vendor-selection decisions.
-
ML385: Practical NRF2 Inhibition Workflows
2026-09-05
ML385 provides a practical pharmacological handle for testing NRF2-dependent antioxidant signaling, therapeutic resistance, and redox-sensitive phenotypes. This workflow connects non-small cell lung cancer research with emerging NRF2 studies in inflammation and osteolysis while emphasizing controls, target engagement, and troubleshooting.
-
VE-821 ATR Kinase Inhibitor Workflow Guide
2026-09-04
VE-821 enables selective ATR checkpoint inhibition for DNA damage response studies, radiosensitization assays, and chemotherapy sensitization workflows. This guide connects practical assay design with the DNMT1-centered HBoV1 findings while clearly separating established product applications from exploratory cross-domain hypotheses.
-
Streptavidin-HyperFluor 647: Assay Design
2026-09-04
Streptavidin-HyperFluor 647 supports sensitive red-fluorescent detection of biotinylated targets. This article presents a readout-first framework for choosing it across microscopy, flow cytometry, FRET, and proximity-labeling workflows.